“Korean biopharmaceutical companies should use U.S. federal government’s R&D support programs”
It was suggested it would be important for Korean biopharmaceutical companies to actively use the Federal Government of the United States’ R&D support program.
Jung-Min Lee at Korea Trade-Investment Promotion Agency(KOTRA) Washington gave an advice in the most recent issue of the KOTRA’s foreign...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.